ECSP21075073A - Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicoactivos - Google Patents

Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicoactivos

Info

Publication number
ECSP21075073A
ECSP21075073A ECSENADI202175073A ECDI202175073A ECSP21075073A EC SP21075073 A ECSP21075073 A EC SP21075073A EC SENADI202175073 A ECSENADI202175073 A EC SENADI202175073A EC DI202175073 A ECDI202175073 A EC DI202175073A EC SP21075073 A ECSP21075073 A EC SP21075073A
Authority
EC
Ecuador
Prior art keywords
cancer
compositions
treatment
methods
psychoactive effects
Prior art date
Application number
ECSENADI202175073A
Other languages
English (en)
Inventor
Jay E Moon
Original Assignee
Powderpost Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72751285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP21075073(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Powderpost Llc filed Critical Powderpost Llc
Publication of ECSP21075073A publication Critical patent/ECSP21075073A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/0288—Applications, solvents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)

Abstract

Algunas realizaciones incluyen una metodología de administración de cannabinoides. En algunas realizaciones, uno o más cannabinoides tales como tetrahidrocannabinol (THC) y / o cannabidiol (CBD) se administran a través de un supositorio rectal o vaginal, o por vía intravenosa, no son psicoactivos. En algunos casos, el THC y / o CBD no son psicoactivos solo cuando se administran de la manera antes mencionada.
ECSENADI202175073A 2019-04-09 2021-10-12 Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicoactivos ECSP21075073A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962831534P 2019-04-09 2019-04-09
PCT/US2019/062979 WO2020209902A1 (en) 2019-04-09 2019-11-25 Methods and compositions for use in treatment of cancer without psychoactive effects

Publications (1)

Publication Number Publication Date
ECSP21075073A true ECSP21075073A (es) 2022-03-31

Family

ID=72751285

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202175073A ECSP21075073A (es) 2019-04-09 2021-10-12 Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicoactivos

Country Status (9)

Country Link
US (1) US20220168238A1 (es)
EP (1) EP3952860A1 (es)
BR (1) BR112021020302A2 (es)
CA (1) CA3136607A1 (es)
CL (1) CL2021002646A1 (es)
CO (1) CO2021013455A2 (es)
EC (1) ECSP21075073A (es)
MX (1) MX2021012400A (es)
WO (1) WO2020209902A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000031379A1 (it) * 2020-12-18 2022-06-18 Curaleaf International Ltd Formulazione farmaceutica topica e metodo per il trattamento delle sindromi associate a dolore pelvico cronico
WO2022137215A1 (en) * 2020-12-24 2022-06-30 Czupiel Petro Pawlo Safe-to-ingest cationic microemulsions and nanoemulsions containing lipophilic components
WO2022165439A1 (en) * 2021-02-01 2022-08-04 Aion Therapeutic Inc. Methods for treatment of human cancers using cannabis compositions
WO2023287742A1 (en) * 2021-07-12 2023-01-19 Integrative Therapy Discovery Lab S.R.L. Use of phytocannabinoids for treating endometrial cancer and endometriosis
IL312245A (en) 2021-10-26 2024-06-01 Ecofibre Usa Inc Methods of treating endometriosis and other non-cancerous gynecological disorders with hemp extract
CA3235078A1 (en) 2021-10-26 2023-04-05 Ecofibre USA Inc. Methods of treating endometrial cancer using hemp extract
WO2023235833A1 (en) * 2022-06-03 2023-12-07 Pctrx, Inc. Polycannabinoid compositions and uses thereof
WO2024091989A1 (en) 2022-10-26 2024-05-02 Ecofibre USA Inc. Stabilized compositions comprising cannabidiol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009308665B2 (en) * 2008-10-31 2015-10-22 The University Of Mississippi Compositions containing delta-9-THC-amino acid esters and process of preparation
US8808734B2 (en) * 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
CA2952335A1 (en) * 2015-12-19 2017-06-19 Delta 9 Gardening B.V. Therapeutic delivery formulations and systems comprising cannabinoids and terpenes
WO2019195943A1 (en) * 2018-04-13 2019-10-17 Urban Juve Provisions Inc. Cannabis root extract, method of manufacture, method of use

Also Published As

Publication number Publication date
EP3952860A1 (en) 2022-02-16
MX2021012400A (es) 2022-05-25
CL2021002646A1 (es) 2022-04-29
CA3136607A1 (en) 2020-10-15
CO2021013455A2 (es) 2022-01-17
WO2020209902A1 (en) 2020-10-15
US20220168238A1 (en) 2022-06-02
BR112021020302A2 (pt) 2021-12-28

Similar Documents

Publication Publication Date Title
ECSP21075073A (es) Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicoactivos
CO2019013887A2 (es) Composiciones y tratamientos para el trastorno del sueño
PE20200677A1 (es) Composicion de cannabis
MX2020003934A (es) Uso de cannabidiol en combinacion con agonistas del receptor 5-ht2b o anfetamina en el tratamiento de la epilepsia.
AR080454A1 (es) Fitocanabinoides en el tratamiento del cancer
MX2020007784A (es) Uso de cannabinoides en el tratamiento de la epilepsia.
CL2017002998A1 (es) Plantas que tienen expresión modificada de thca sintasa
SV2017005489A (es) Terapias de combinación para el tratamiento de cánceres
PE20200726A1 (es) Composicion de cannabis
MX2020006965A (es) Formulacion farmaceutica oral que comprende cannabinoides y poloxamero.
UA104426C2 (uk) Протипухлинні ефекти комбінацій канабіноїдних сполук
CO2023011071A2 (es) Agonistas del receptor gpcr, composiciones farmacéuticas que los comprenden y métodos para su uso
MX2014002873A (es) Fitocanabinoides que pueden usarse en el tratamiento del cancer.
CO6290695A2 (es) Uso de canabinoides en combinación con un medicamento antisicótico.
UY37168A (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
AR088391A1 (es) Fitocanabinoides para usar en el tratamiento de cancer de mama
PE20211650A1 (es) Composicion y metodo para tratar el dolor
DOP2012000063A (es) (heteroarilmetil) tiohidantoinas sustituidas como drogas anticancer
CO2021001057A2 (es) Composición y método para el ahorro de opioides
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
MX2020012800A (es) Cannabinoides y usos de los mismos.
CO2019008831A2 (es) Composición química
GB2564459A8 (en) Use of cannabinoids in the treatment of a neurodegenerative disease or disorder
CL2020003374A1 (es) Composicion y metodo de cannabinoides para tratar el tept y/o la ansiedad
CL2021000329A1 (es) Compuestos útiles en terapia del vih